



October 13, 2016

TransEnterix to Feature Senhance™ Surgical Robot at American College of Surgeons Clinical Congress

Opportunity for thousands of global attendees to see and interact with new robot

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance™ Surgical Robot ("the Senhance" or "the Senhance system") at the Clinical Congress 2016 of the American College of Surgeons (ACS). The congress will be held on October 16-20, 2016 in Washington, DC.

"ACS is the largest gathering of global surgeons, and we are pleased to bring the Senhance System to exhibit at this major meeting for the first time," said Mohan Nathan, Vice President of Global Marketing at TransEnterix. "General surgical interest in the use of robotics is rapidly expanding, and the next wave of adoption will be driven by providing surgeons with new capabilities. Senhance is the first system that brings haptic force feedback, eye-sensing camera control, and responsible economics through reusable instrumentation to robotics."

The Senhance will be available for surgeon evaluations at the congress. Surgeons may schedule system evaluations by signing up at the TransEnterix booth. Non-surgeons may see demonstrations throughout the conference, and may also attend a group demonstration at the booth at 10am on Tuesday, October 18, 2016.

The Senhance carries the CE Mark for use in general surgery, gynecology, urology and thoracic surgery but is not available for sale in the US. TransEnterix is preparing a submission for U.S. FDA Clearance for the Senhance.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to The Senhance™ Surgical Robotic System and the SurgiBot™ System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20161013005061/en/>

For TransEnterix, Inc.

Investor Contact:

Mark Klausner, +1 443-213-0501

invest@transenterix.com

or

Media Contact:

(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For US) Hannah Dunning, +1 415-618-8750
TransEnterix-SVC@sardverb.com

Source: TransEnterix, Inc.

News Provided by Acquire Media